Week in Review: Bio-Thera Raises $241 Million in Shanghai STAR IPO for Antibody Portfolio

Deals and Financings • Bio-Thera Solutions of Guangzhou priced its $241 million IPO on Shanghai’s STAR Board at a $2 billion valuation to support its antibody pipeline; • Shanghai Universal Medical Imaging closed an $86 million Series B round to expand its portfolio of China third-party imaging centers; • China's TUS-Holdings participated in a $22 million B round for Stilla Technologies of Paris and its PCR device that detects/quantifies DNA mutations; • Beijing Advaccine Biotechnology raised $4.3 million to test a COVID-19 being developed with Inovio of the US; Wuhan Coronavirus Outbreak • BrightGene Bio-Medical of Suzhou synthesized the API of remdesivir, a Gilead drug with China IP aimed at COVID-19, and would like to produce the drug; • Sihuan Pharma and Hetero Labs, an Indian generic drug maker, signed a framework agreement to bring Hetero's products, including potential COVID-19 anti-infectives, to China; • Johnson & Johnson will collaborate with the US Biomedical Advanced Research and Development Authority to expedite development of a COVID-19 vaccine; • Clover Bio of Chengdu has produced a trimeric Spike-protein (S-Trimer) subunit vaccine candidate for the Wuhan coronavirus; Trials and Approvals • Roche announced China approval to launch its PD-L1 immunotherapy, Tecentriq, to treat small cell lung cancer; • Genetron Holdings of Beijing received NMPA approval to market its 8-gene Lung Cancer Assay for risk assessment and early cancer screening; • Samsung Bioepis, a biosimilar JV formed by Korea's Samsung and Biogen, will start a China Phase III trial of a biosimilar to a treatment for a rare disease, PNH; • Zai Lab reported China's NMPA has accepted for review its NDA for omadacycline, a novel anti-infective. Stock Symbols: (SHA: 688177) (SHA: 688166) (NSDQ: GILD) (HKEX: 0460) (NYSE: JNJ) (SIX: ROG) (NSDQ: ZLAB) Share this with colleagues: // //